Prospective Management of Regulatory Risks: Securing the Longevity of Biocidal Assets

In a context of continuous tightening of the European regulatory framework, the longevity of a biocidal portfolio no longer relies solely on immediate compliance, but on its resilience to future reassessments. For major chemical players, "Future-Proofing" (long-term security) has become an imperative to avoid technological obsolescence and unforeseen substitution costs.

Active Substance Monitoring and Anticipation of Exclusion Criteria

The Biocidal Products Regulation (BPR) provides for periodic review processes that can lead to the exclusion or severe restriction of certain conventional substances (Quats, Chlorine, Alcohols).

Exclusion Criteria (Art. 5): ECHA is intensifying its scrutiny on substances exhibiting Endocrine Disrupting (ED) properties or classified as CMR (Carcinogenic, Mutagenic, Reprotoxic). Anticipating these classifications is crucial to prevent the sudden withdrawal of products from the market.
Management of Impurities and By-products: Upstream monitoring of chemical impurity profiles is a safety lever to prevent dossier invalidation during approval renewal phases.

Strategic Substitution with Annex I Substances

Adopting technologies based on low-risk substances listed in Annex I (such as Lactic Acid) constitutes the most robust risk management strategy.

Reduction of Legal Exposure: The use of inherently safe substances eliminates risks related to occupational health and environmental civil liability.
Absence of CLP Classification: By formulating “Unclassified” products, manufacturers free themselves from anxiety-inducing labeling constraints for the end-user and complex requirements for Personal Protective Equipment (PPE).
Regulatory Stability: Unlike active substances under surveillance, Annex I substances offer 10-year visibility, guaranteeing stable exploitation of simplified marketing authorizations (SMA).

Alignment of Biocidal Assets with ESG Standards

Regulatory safety now converges with extra-financial performance. For large groups, portfolio sustainability is a key CSR/ESG (Environmental, Social, Governance) performance indicator.

Biodegradability and Ecotoxicological Profile: Solutions derived from the Salveco technological platform guarantee 100% biodegradability, meeting the requirements for environmental impact reduction.
Valuation of Intangible Assets: A legally and technically secured biocidal portfolio holds a higher book value, as it is not exposed to risk provisions related to controversial substances.

Securing a biocidal portfolio today requires cross-disciplinary expertise combining fine chemistry and prospective regulatory monitoring. By prioritizing patented solutions that comply with the strictest ECHA requirements and are free from substances of concern, chemical leaders transform compliance into a lever for resilience and competitiveness.

Key Takeaways for Prospective Audits:

Continuous monitoring of ECHA developments regarding endocrine disruptors.
Proactive substitution of at-risk active substances with “Annex I compliant” technologies.
ESG valuation through the elimination of hazard pictograms (GHS05, GHS07).

Salveco provides its expertise to audit the longevity of your product ranges and design secure substitution strategies. Contact our Regulatory Affairs department.